Chile’s National Economic Prosecutor (FNE) has presented its counterpart, the Tribunal for the Defense of Free Competition (TDLC) with charges against local drug-makers Laboratorio Biosano, Fresenius Kabi Chile and its affiliate Laboratorio Sanderson. Authorities have accused the companies of forming a decade-long arrangement to rig government contract bidding. The labs are the country’s only makers of medical ampoules for generic medication.
The FNE charges accuse the labs of rigging bids for supplying the national health system by defining beforehand which of the two would be the winner of each contest. The cartel would coordinate reference prices and adjust their offers to ensure the ‘right’ company would win a specific contract.
The FNE has asked for a fine of 18 thousand UTA units for Sanderson and 2 thousand UTA units for Biosano, bringing the total to around $17 million USD. Biosano was able to avoid sanctions due to its cooperation under Chile’s leniency program for antitrust violators.
Full Content: La Tercera
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI